Educational research reference · Not medical advice · Compounds discussed are research materials, not approved drugs
Home / Protocols / Semax
Protocol · Research Dosing Guide

Semax Dosing Protocol: Nasal Spray, Injection, Reconstitution & Research (2026)

A research reference for the nootropic peptide Semax, with separate nasal-spray and injection protocols, reconstitution math, mechanism, and safety context. Intranasal is the classic research route for Semax.

Semax Quick Start

Semax is a synthetic heptapeptide derived from a fragment of ACTH (adrenocorticotropic hormone), developed in Russia as a nootropic and neuroprotective agent. It is studied for cognition, focus, stress resilience, and recovery in neurological models, and is approved in Russia for several neurological indications. Intranasal delivery is the classic route.

Quick reference Nootropic peptide
Class
ACTH(4–10) heptapeptide
Formats
Nasal spray · Vial (SubQ)
Research focus
Cognition, neuroprotection
Classic route
Intranasal
Vial size
10 mg

This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.

Semax Dosing Protocols

The nasal-spray and injectable (subcutaneous) formats are documented as two separate protocols. Intranasal is the traditional Semax route, so the spray maps naturally to most published and community research. Ranges are research-planning references, not personal dosing recommendations.

Nasal Spray (classic route)

Pre-mixed nasal spray, ready to use.
BandPer dose# of spraysFrequency
Low200 mcg2 sprays1–2× daily
Standard400 mcg4 sprays1–2× daily
High600 mcg6 sprays1–2× daily
Each 0.1 mL spray delivers 100 mcg

Injection — Subcutaneous

Reconstituted 10 mg vial, U-100 insulin syringe.
BandPer doseFrequency
Low200 mcg1–2× daily
Standard400 mcg1–2× daily
High600 mcg1–2× daily
10 mg + 2 mL BAC → 5,000 mcg/mL · 200 mcg = 4 units

Semax is short-acting; split daily dosing appears frequently in research planning. It is often researched in blocks of a few weeks. (N-Acetyl Semax is a separate, longer-acting variant.)

Semax Reconstitution Guide

Semax ships as a lyophilized powder. The BAC water volume sets the concentration and draw volume for the injectable vial. Nasal sprays ship pre-mixed and ready to use.

Injection

BACConc.200 mcg
2 mL5,000 mcg/mL0.04 mL · 4 u
3 mL3,333 mcg/mL0.06 mL · 6 u

Vial holds up to ~3 mL; 2 mL is the default. Units are U-100.

Reconstitution steps

  1. Inspect the vial. Confirm label and intact powder.
  2. Wipe the stoppers. Alcohol swab on both vials.
  3. Draw BAC water. 2–3 mL into the vial for injection (vial max ~3 mL).
  4. Inject down the wall. Release water slowly down the inside wall, not onto the powder.
  5. Swirl, do not shake. Roll gently until clear.
  6. Refrigerate. Store at 2–8 °C; do not freeze.

How to use the nasal spray

  1. Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
  2. Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
  3. Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
  4. Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
  5. Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
  6. Between uses. Wipe the tip, recap, and refrigerate.

How Semax Works

Semax is an analog of the ACTH(4–10) fragment but, unlike ACTH, it does not stimulate cortisol release. Research reports that it increases expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), modulates dopaminergic and serotonergic activity, and has neuroprotective and anti-inflammatory effects in the central nervous system. Its activity is enhanced by being relatively resistant to breakdown compared with the parent fragment.

BDNF / NGF

Reported to upregulate neurotrophic factors linked to neuronal survival and plasticity.

Neurotransmitters

Modulates dopaminergic and serotonergic signaling in research models.

Neuroprotection

Animal stroke/ischemia models report protective and recovery effects.

No cortisol effect

Despite the ACTH origin, Semax does not drive corticosteroid release.

Who Should Avoid Semax

Pregnancy & lactation

No human reproductive safety data outside its approved use context.

On psychoactive medications

Interactions with dopaminergic/serotonergic drugs aren't characterized; review with a clinician.

Nasal pathology

Active nasal injury or infection may make the intranasal route unsuitable.

Anyone seeking a treatment

Treat Semax as research context only, not a medical treatment.

Semax Side Effects & Safety

Generally well tolerated

In its approved-use context and research, Semax has a mild reported side-effect profile.

Nasal irritation

Mild irritation can occur with the intranasal route; alternate nostrils.

Overstimulation

Some users report feeling stimulated or alert; dose/timing adjustments are the usual response.

Quality-control risk

Verify identity and purity against a Certificate of Analysis.

Timeline & What to Monitor

TimeframeCommonly trackedNotes
Same dayFocus / alertness self-reportSemax is short-acting; effects are evaluated acutely.
Week 1–3Cognitive/mood self-report over a blockMost community research runs in multi-week blocks.
OngoingNasal tolerance (intranasal route)Alternate nostrils; pause if irritation persists.

Research Evidence Context

Russian clinical use

Approved in Russia for stroke, cognitive, and optic-nerve indications, supported by regional clinical data.

Neurotrophic research

Studies report BDNF/NGF upregulation and neuroprotection in animal and cell models.

Western evidence

Large Western RCTs are limited; outside Russia it is treated as research-use.

Open question

Translation of cognitive benefits to healthy-user contexts is not well established.

Storage & Handling

StateStorageNotes
Lyophilized (powder)−20 °C long-term; fridge short-termMore stable than reconstituted solution.
Reconstituted (liquid)2–8 °CUse within ~3–4 weeks; do not freeze.
AppearanceClear, colorlessDiscard cloudy or particulate solutions.

Mistakes & Troubleshooting

  1. Nasal irritation. Alternate nostrils; pause if it persists. Consider the injectable format.
  2. Feeling over-stimulated. Lower the dose or avoid late-day administration.
  3. Missed dose. Skip and continue at the next scheduled time; Semax is short-acting.
  4. Left out overnight. Treat reconstituted solution as compromised and discard.

Semax vs Selank vs N-Acetyl Semax

FeatureSemaxN-Acetyl Semax
ProfileACTH(4–10) nootropic, short-actingAcetylated, longer-acting variant
RouteIntranasal / SubQIntranasal / SubQ
FocusCognition, focus, neuroprotection; often compared with the anxiolytic peptide Selank.

Frequently Asked Questions

What is Semax?

A synthetic heptapeptide based on an ACTH fragment, developed in Russia as a nootropic and neuroprotective agent. It is approved in Russia for some neurological indications.

How is the nasal spray dosed vs the injection?

Separate protocols. Intranasal is the classic route: the spray delivers 100 mcg per spray, so 2–6 sprays covers the 200–600 mcg research range. Injection covers the same range subcutaneously.

How is Semax reconstituted?

The spray ships pre-mixed and delivers 100 mcg per spray. For injection, 10 mg in 2 mL gives 5,000 mcg/mL, so 200 mcg = 0.04 mL = 4 units.

Does Semax raise cortisol like ACTH?

No. Although it is derived from an ACTH fragment, Semax does not stimulate corticosteroid release.

Is this page medical advice?

No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.

References

  1. Ashmarin IP, et al. Semax: an ACTH(4–10) analog with nootropic properties. Neurosci Behav Physiol (review).
  2. Dolotov OV, et al. Semax and BDNF expression in the rat hippocampus. J Neurochem / Neurosci Lett (2006).
  3. Medvedeva EV, et al. Semax in cerebral ischemia models. Mol Biol / J Mol Neurosci (2014).
  4. Kaplan A, et al. Clinical use of Semax in ischemic stroke. Zh Nevrol Psikhiatr (review).